Univ Biotech released its 2026 interim report, with total operating revenue of 569 million yuan and net profit attributable to the parent company of negative 11.7958 million yuan, ranking 37th among disclosed peer companies. Net cash flow from operating activities was negative 163 million yuan, a decrease of 101 million yuan compared with the same period last year. The company's latest asset-liability ratio was 14.07%, gross margin was 20.59%, ROE was negative 0.61%, and diluted earnings per share was negative 0.14 yuan. The number of shareholders was 9,482, and the top ten shareholders held 58.05% of the shares.
Shanghai Universal Biotech Co.Ltd.Net loss of 11.7958 million yuan and negative operating cash flow in interim report.